The anti-angiogenic action of 2-deoxyglucose involves attenuation of VEGFR2 signaling and MMP-2 expression in HUVECs.

AIMS 2-Deoxyglucose (2-DG) is a glucose analogue and has been shown to inhibit angiogenesis in human umbilical vascular endothelial cells (HUVECs) through interference with N-linked glycosylation. However, the anti-angiogenic mechanisms of 2-DG are not fully elucidated. MAIN METHODS We first employed an ex vivo rat aortic ring model to substantiate the anti-angiogenic action of 2-DG and then used HUVECs to investigate the molecular mechanism underlying such an action. KEY FINDINGS Results reveal that 2-DG (0.05-1.0mM) significantly inhibited tube formation in both rat aortic rings and HUVECs. 2-DG (0.1-1.0mM) also significantly inhibited cell invasion and migration, as well as the activity and mRNA and protein expression of matrix metalloproteinase (MMP)-2 in HUVECs. In addition, 2-DG (1.0mM) significantly inhibited mRNA and protein expression of vascular endothelial growth receptor 2 (VEGFR2) in a time-dependent manner. 2-DG also significantly inhibited the phosphorylation of the focal adhesion kinase (FAK) and mitogen-activated protein kinase (p38), the downstream molecules of VEGFR2. The effects of 2-DG on tube formation, MMP-2 activity, and VEGFR2 protein expression in HUVECs were reversed by mannose, an N-linked glycosylation precursor. Mannose also reversed 2-DG-induced accumulation of VEGFR2 in the endoplasmic reticulum. SIGNIFICANCE This ex vivo and in vitro study demonstrates that 2-DG inhibits angiogenesis with an action involving attenuation of VEGFR2 signaling and MMP-2 expression, possibly resulting from interference with N-linked glycosylation of VEGFR2. Further studies are needed to show that 2-DG inhibits VEGF-mediated angiogenesis or that the actual status of N-glycosylation of VEGFR2 is affected by the treatment.

[1]  Chih-min Yang,et al.  Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways. , 2012, Molecular nutrition & food research.

[2]  H. Kleinman,et al.  Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures , 1988, The Journal of cell biology.

[3]  M. Rogawski,et al.  Anticonvulsant and proconvulsant actions of 2‐deoxy‐d‐glucose , 2010, Epilepsia.

[4]  M. L. Mena,et al.  2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways. , 2012, Biochemical pharmacology.

[5]  M. Caputi,et al.  Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors. , 2011, Current drug targets.

[6]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[7]  D. Thamm,et al.  Glycolysis inhibition by 2-deoxy-d-glucose reverts the metastatic phenotype in vitro and in vivo , 2011, Clinical & Experimental Metastasis.

[8]  Venkata Reddy Bandugula,et al.  2-Deoxy-d-glucose and ferulic acid modulates radiation response signaling in non-small cell lung cancer cells , 2013, Tumor Biology.

[9]  B. Potter,et al.  2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer , 2008, British Journal of Cancer.

[10]  R. Nicosia,et al.  Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[11]  R. Schwarz,et al.  Interference with glycosylation of glycoproteins. Inhibition of formation of lipid-linked oligosaccharides in vivo. , 1979, The Biochemical journal.

[12]  Kevin Bray,et al.  Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignancies , 2010, The Prostate.

[13]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[14]  M. Kurtoğlu,et al.  Antiangiogenic Activity of 2-Deoxy-D-Glucose , 2010, PloS one.

[15]  J. Niewiarowska,et al.  [Mechanisms of cancer angiogenesis]. , 2009, Postepy higieny i medycyny doswiadczalnej.

[16]  R. Schwarz,et al.  Fluorosugars inhibit biological properties of different enveloped viruses , 1976, Journal of virology.

[17]  S. Rafii,et al.  Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. , 2000, The Journal of clinical investigation.

[18]  C. Unkefer,et al.  Synthesis of 2-deoxy-D-arabino-(6-13C)hexose. , 1988, Carbohydrate research.

[19]  B. Dwarakanath,et al.  Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. , 1996, International journal of radiation oncology, biology, physics.

[20]  Katherine Holmes,et al.  Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. , 2007, Cellular signalling.

[21]  A. Wilks,et al.  NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo. , 1993, Oncogene.

[22]  T. Haas.  Endothelial cell regulation of matrix metalloproteinases. , 2005, Canadian journal of physiology and pharmacology.

[23]  N. Yang,et al.  Effects of 2-deoxyglucose and dehydroepiandrosterone on intracellular NAD+ level, SIRT1 activity and replicative lifespan of human Hs68 cells , 2011, Biogerontology.

[24]  A. Lane,et al.  Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation , 2007, Molecular Cancer Therapeutics.

[25]  Stuart M Haslam,et al.  The Antifungal Drug Itraconazole Inhibits Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, Trafficking, and Signaling in Endothelial Cells* , 2011, The Journal of Biological Chemistry.

[26]  H. Freeze,et al.  Mannose Enters Mammalian Cells Using a Specific Transporter That Is Insensitive to Glucose (*) , 1996, The Journal of Biological Chemistry.

[27]  Jing-Jy Cheng,et al.  Study for anti-angiogenic activities of polysaccharides isolated from Antrodia cinnamomea in endothelial cells. , 2005, Life sciences.

[28]  Johnathan C. Maher,et al.  Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. , 2007, Antioxidants & redox signaling.

[29]  A. Ullrich,et al.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.

[30]  P. Shaw,et al.  Dynamics of vascular endothelial-cadherin and beta-catenin localization by vascular endothelial growth factor-induced angiogenesis in human umbilical vein cells. , 2002, Experimental cell research.

[31]  J. Pirayesh Islamian,et al.  Enhanced Radiosensitivity and Chemosensitivity of Breast Cancer Cells by 2-Deoxy-D-Glucose in Combination Therapy , 2012, Journal of breast cancer.

[32]  L. Kotra,et al.  N-Glycosylation pattern of the zymogenic form of human matrix metalloproteinase-9. , 2002, Bioorganic chemistry.

[33]  H. Lodish.  Molecular Cell Biology , 1986 .

[34]  M. Pepper.  Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis , 2001, Arteriosclerosis, thrombosis, and vascular biology.